Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gartner Inc (IT) vs Moderna, Inc. (MRNA) Price & Performance

Gartner IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Gartner Inc vs Moderna, Inc. — how do they compare? Gartner Inc trades at $181.72 (market cap $11.83B), while Moderna, Inc. trades at $63.36 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 2× Gartner Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, Gartner Inc nearer its low. Which is the better fit depends on your goals.

ITMRNA
Market Cap
$11.83B$24.18B
Sector
TechnologyHealth
52-Week High
$264.09$81.80
52-Week Low
$125.68$22.36
Enterprise Value
$13.57B$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gartner Inc

Gartner (IT) trades at $185.09, down 4.18% today, following a strong earnings beat in Q2 2026 with EPS of $4.37 versus $3.76 expected. The stock shows a bullish technical trend but trades above the consensus price target of $172.80. Recent news highlights a shareholder investigation and raised full-year EPS guidance, creating mixed sentiment amid strong profitability metrics like a 69.63% gross margin and 113.58% ROE.

The outlook is cautiously optimistic given earnings momentum and valuation discounts, but risks include consulting segment weakness, negative net cash flow trends, and the fiduciary investigation. Upside depends on sustained execution against guidance, while downside could stem from growth deceleration or legal overhangs.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

About Gartner Inc

Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.

Read more on IT

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA